Furthermore, because CGA is known to influence MAPK and PI3K/Akt signaling pathways [96], combination therapy with Regorafenib has been explored [97], which is a multikinase inhibitor used in the treatment of refractory advanced colon cancer [98]. This evidence concerns the gene AKT1 and colonic neoplasm.